<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01857167</url>
  </required_header>
  <id_info>
    <org_study_id>DUOLI2013011</org_study_id>
    <nct_id>NCT01857167</nct_id>
  </id_info>
  <brief_title>Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Natural Science Foundation of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <brief_summary>
    <textblock>
      This study is to examine the change of fasting insulin, glucose, insulin sensitivity and
      related traits in response to the six month treatment of omega-3 fatty acids, including fish
      oil and flaxseed oil, in Chinese type 2 diabetic patients. Corn oil, rich in omega-6 fatty
      acids, will be selected as a controlled oil. The investigators hypothesize that omega-3 fatty
      acids could improve insulin sensitivity and glucose metabolism in Chinese type 2 diabetic
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The insulin resistance will be estimated by a homeostatic model assessment model of insulin
      resistance (HOMA-IR)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Type 2 Diabetes</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Fish Oil Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive fish oil capsules, at a dose of 4g/day. Each 1g capsule will contain 300mg of EPA and 200mg of DHA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flaxseed Oil Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive flaxseed oil capsule, at a dose of 4g/day. Each 1g capsule will contain 630mg of ALA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Supplementation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive corn oil in the capsules at the same dose as fish oil. The corn oil will appear identical in size and color to the fish oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil Supplementation</intervention_name>
    <arm_group_label>Fish Oil Supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flaxseed Oil Supplementation</intervention_name>
    <arm_group_label>Flaxseed Oil Supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo Supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fasting glucose &gt; 7.0 or have diabetes medication;

          2. Male, 35-80 years; female, postmenopausal to 80 years;

          3. Agree to participant in the trial.

        Exclusion Criteria:

          1. Deny to sign the informed consent;

          2. type 1 diabetes;

          3. Family history of hypertriglyceridemia or fasting triglyceride&gt;4.56 mmol/L;

          4. Have severe liver disease, kidney disease or cancer;

          5. Participating in the other clinical trial within 30 days;

          6. Other diseases or conditions, for which the doctor of the patients do not agree his or
             her participating.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310058</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zheng JS, Huang T, Yang J, Fu YQ, Li D. Marine N-3 polyunsaturated fatty acids are inversely associated with risk of type 2 diabetes in Asians: a systematic review and meta-analysis. PLoS One. 2012;7(9):e44525. doi: 10.1371/journal.pone.0044525. Epub 2012 Sep 11. Review.</citation>
    <PMID>22984522</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2013</study_first_submitted>
  <study_first_submitted_qc>May 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2013</study_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Duo li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>omega-3 fatty acids</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

